NOVAVAX, INC. Form 8-K (Aug. 10, 2020) — Item 2.02

Summary

Current report on Form 8-K of Novavax, Inc. dated August 10, 2020, reporting under Item 2.02, Results of Operations and Financial Condition. The company states that on August 10, 2020 it issued a press release announcing financial results for the quarter ended June 30, 2020, attached as Exhibit 99.1. The report states the information in Items 2.02 and 9.01 is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The signature block is John A. Herrmann III, Executive Vice President, Chief Legal Officer and Corporate Secretary, dated August 11, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event
reported): August 10, 2020

NOVAVAX, INC.

(Exact name of registrant as specified
in charter)

Delaware | 0-26770 | 22-2816046
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

21 Firstfield Road

Gaithersburg , Maryland 20878

(Address of Principal Executive Offices,
including Zip Code)

(240) 268-2000

(Registrant’s telephone number,
including area code)

(Former name or former address, if changed
since last report.)

________________________________________________________

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.01 per share | NVAX | The Nasdaq Global Select Market

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):

¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

Second Quarter Financial Results

On August 10,
2020, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the
quarter ended June 30, 2020. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information
in Items 2.02 and 9.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or
the Exchange Act except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description
99.1 | Press release, dated August 10, 2020, regarding the Company’s financial results for the quarter ended June 30, 2020.
104 | Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

NOVAVAX, INC.
Date: August 11, 2020 | By: | /s/ John A. Herrmann III
Name: Title: | John A. Herrmann III Executive Vice President, Chief Legal Officer and Corporate Secretary

File and source

File

SEC_NVAX_8-K_filed2020-08-11_0001104659-20-093287.htm

Size

27,093 bytes

SHA-256

c4cc0e8e890f50255044ddffb4c129a0d08cfe1aa358ae7fbaa4db0f33dcf995

Our copy

SEC_NVAX_8-K_filed2020-08-11_0001104659-20-093287.htm

Original

www.sec.gov